Ronald Tutrone
Overview
Explore the profile of Ronald Tutrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calais J, Morris M, Kendi A, Kalebasty A, Tutrone R, Anderson M, et al.
J Nucl Med
. 2024 Oct;
65(11):1666-1671.
PMID: 39362764
Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent...
2.
Saad F, Hussain M, Tombal B, Fizazi K, Sternberg C, Crawford E, et al.
Eur Urol
. 2024 Apr;
86(4):329-339.
PMID: 38644146
Background And Objective: Addition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and...
3.
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Spratt D, George D, Shore N, Cookson M, Saltzstein D, Tutrone R, et al.
JAMA Oncol
. 2024 Mar;
10(5):594-602.
PMID: 38451492
Importance: Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. Objective: To assess the efficacy and safety of the oral gonadotropin-releasing...
4.
Tutrone R, Saad F, George D, Tombal B, Bailen J, Cookson M, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):906-913.
PMID: 38143206
Background: In the HERO study, relugolix demonstrated sustained testosterone suppression superior to that of leuprolide acetate (97% vs 89%; difference 7.9% [95% confidence interval, 4.1-12%; p < 0.001]). Objective: To...
5.
Saad F, George D, Cookson M, Saltzstein D, Tutrone R, Bossi A, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835548
Relugolix is an oral GnRH receptor antagonist approved for men with advanced prostate cancer. Relugolix treatment has demonstrated an ability to lower testosterone to sustained castration levels in the phase...
6.
Shore N, Mehlhaff B, Cookson M, Saltzstein D, Tutrone R, Brown B, et al.
Adv Ther
. 2023 Sep;
40(11):4919-4927.
PMID: 37713020
Introduction: Cardiovascular (CV) events are the leading cause of death in prostate cancer. Men with prostate cancer are likely to have CV risk factors and use CV-related concomitant medications. In...
7.
Tutrone R, Lowentritt B, Neuman B, Donovan M, Hallmark E, Cole T, et al.
Prostate Cancer Prostatic Dis
. 2023 Jun;
27(1):161.
PMID: 37337052
No abstract available.
8.
Tutrone R, Lowentritt B, Neuman B, Donovan M, Hallmark E, Cole T, et al.
Prostate Cancer Prostatic Dis
. 2023 May;
26(3):596-601.
PMID: 37193776
Background: Patient outcomes were assessed based on a pre-biopsy ExoDx Prostate (EPI) score at 2.5 years of the 5-year follow-up of ongoing prostate biopsy Decision Impact Trial of the ExoDx...
9.
George D, Saad F, Cookson M, Saltzstein D, Tutrone R, Bossi A, et al.
Clin Genitourin Cancer
. 2023 Apr;
21(3):383-392.e2.
PMID: 37062659
Background: To characterize the impact of concomitant prostate cancer treatments with the use of relugolix, the oral GnRH receptor antagonist, in advanced prostate cancer, a subgroup and pharmacokinetic/pharmacodynamic analyses of...
10.
De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R, et al.
Target Oncol
. 2023 Apr;
18(3):383-390.
PMID: 37060432
Background: Androgen deprivation therapy (ADT), a cornerstone of prostate cancer treatment, is commonly co-prescribed as combination therapy. Objective: To better understand the safety and tolerability profile of relugolix, an oral...